Login


Meet the Advisors behind GoodCell

David Scadden, MD GoodCell photo

David Scadden, M.D., D.Sc (Hon)

Co-founder and Chair of GoodCell's Scientific Advisory Board
Co-founder of Harvard Stem Cell Institute
Director, Center for Regenerative Medicine at MGH
Professor, Harvard University

David Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He and Professor Douglas Melton founded and jointly direct the Harvard Stem Cell Institute that is the largest institute dedicated to bringing stem cell biology to medical care in the world.

He is a hematologist/oncologist and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and previously chaired the Hematologic Malignancies program in the MGH Cancer Center. He is an expert on the medical applications of stem cell biology with a particular emphasis on their use in the settings of cancer and AIDS. He has published over 300 scientific papers and book chapters and his laboratory has made fundamental contributions in how the stem cell niche regulates stem cell function and in normal and disease-corrupted hematopoiesis. He is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences and awards from the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Welcome Fund and the Leukemia and Lymphoma Society. He is the recipient of multiple honorary degrees.


Joseph Wu, MD GoodCell photo

Joseph C. Wu, MD, Ph.D

Director, Stanford Cardiovascular Institute
Professor, Stanford University

Director of the Stanford Cardiovascular Institute and Simon H. Stertzer Professor of Medicine and Radiology at the Stanford School of Medicine. Dr. Wu received his MD from Yale University School of Medicine. He trained in internal medicine and cardiology at UCLA followed by a PhD in the Dept of Molecular Pharmacology. His clinical interests involve cardiovascular imaging and adult congenital heart disease. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients.


Kevin Eggan, PhD GoodCell Photo

Kevin Eggan, Ph.D

Principal Investigator, Harvard Stem Cell Institute
Director, Stem Cell Biology, Stanley Center for Psychiatric Research at the Broad Institute
Professor, Harvard University

Dr. Eggan received his Ph.D. from the Department of Biology at MIT, where he made important contributions to understanding the mechanisms that can contribute to cellular reprogramming. Following his doctoral studies, he launched his own group in the Department of Molecular and Cellular Biology at Harvard University. There his laboratory was the first to show that human adult cells can be reprogrammed to pluripotentcy and to produce patient-specific induced pluripotent stem (iPS) cells. Currently, Dr. Eggan is a Professor of Stem Cell and Regenerative Biology at Harvard University, where his research group continues to improve approaches for reprogramming as well as pursue strategies for using iPS cells in the development of new therapeutics.


Steve McCarroll, PhD GoodCell photo

Steve McCarroll, Ph.D

Dir. of Genetics Broad Institute Stanley Center for Psychiatric Research
Professor, Harvard Medical School

McCarroll's training has been broadly interdisciplinary with mentorship in many fields of science. He studied mathematics and economics as an undergraduate at Stanford University, doing research on industrial organization. McCarroll began working in molecular neuroscience with Dr. Cori Bargmann in 1997 and received his PhD in neuroscience from UC San Francisco for that work in 2004. He trained as a postdoctoral fellow in human genetics and genomics with Dr. David Altshuler, where his work revealed how genes and genomic segments commonly vary in copy number from person to person. He started his own lab at Harvard Medical School in 2009.

McCarroll and the scientists in his lab have developed many novel ways to use genomes and genome sequences to understand human biology and the molecular basis of disease. His lab has uncovered surprising ways in which genes and alelles shape risk of human diseases – from schizophrenia to cardiovascular illness to cancer.

Many of the discoveries from McCarroll's lab have involved unexpected insights arising from their new ways of analyzing genome sequences. For example, while studying DNA derived from people's blood samples, his lab discovered a common pre-cancerous state in which blood stem cells have acquired somatic mutations and then clonally expanded, creating a reservoir of pre-cancerous cells that greatly increases risk of developing cancer later in life. His lab also discovered that the human genome replicates (copies itself) in ways that vary from person to person and are shaped by inherited genetic variation.


Jerome Ritz, MD GoodCell photo

Jerome Ritz, M.D

Professor, Harvard Medical School
Professor, Dana Farber Cancer Institute (DFCI)
Executive Director, Connell O'Reilly Cell Manipulation and Gene Transfer Laboratory at DFCI

Dr. Ritz is Executive Director of the Connell-O'Reilly Cell Manipulation Core Facility (CMCF) and a Professor of Medicine at Harvard Medical School. The CMCF provides hematopoietic stem cells for patients who are undergoing hematopoietic stem cell transplantation and manufactured cellular products of various types for patients enrolled on clinical trials evaluating novel cellular therapies for cancer. Dr. Ritz is a member of the Executive Committee of the Dana-Farber/Harvard Cancer Center and the Associate Director for Core Facilities at DF/HCC. He is a Co-Director of the Cancer Vaccine Center at the Dana-Farber Cancer Institute and a member of the Executive Committee of the Harvard Stem Cell Institute. Dr. Ritz's current laboratory research focuses on immune reconstitution after hematopoietic stem cell transplantation, cellular therapies and immunotherapy of cancer.

Save your healthiest cells today

Learn More